Neurogene (NASDAQ:NGNE) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research note released on Tuesday,Benzinga reports. The firm currently has a $70.00 price objective on the stock.

NGNE has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research report on Wednesday, October 8th. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Neurogene currently has a consensus rating of “Hold” and a consensus price target of $42.50.

Neurogene Trading Down 1.9%

NGNE opened at $16.95 on Tuesday. Neurogene has a 1-year low of $6.88 and a 1-year high of $37.27. The stock has a market capitalization of $262.56 million, a PE ratio of -4.12 and a beta of 1.60. The firm has a 50-day moving average price of $21.30 and a two-hundred day moving average price of $22.11.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.27. On average, research analysts predict that Neurogene will post -4.27 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NGNE. Balyasny Asset Management L.P. bought a new stake in Neurogene in the third quarter valued at about $12,114,000. Jennison Associates LLC grew its position in shares of Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after buying an additional 59,479 shares during the period. Bank of America Corp DE increased its stake in shares of Neurogene by 81.6% in the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after acquiring an additional 42,880 shares during the last quarter. Schroder Investment Management Group acquired a new stake in shares of Neurogene in the 2nd quarter valued at approximately $451,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Neurogene in the 3rd quarter valued at approximately $223,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.